Drugs / INXN-3001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00815607 | Apr 2009 → Jan 2013 | melanoma | Alaunos Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INXN-3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00815607 ↗ |
| Modality | Cell therapy | “Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12” NCT00815607 ↗ |
| Route | Other | “Intratumoral injection” NCT00815607 ↗ |